Protelos ‘unique’ among osteoporosis treatments
pharmafile | March 21, 2006 | News story | Sales and Marketing |Â Â Â
Servier says new data on its osteoporosis treatment Protelos shows it reduces women's long-term risk of bone fractures by a third, and argue its efficacy should make it a first line treatment.
A newly published five-year study suggests Protelos gives unique and sustained benefits against vertebral and non-vertebral fractures in postmenopausal women with osteoporosis.
Lead study investigator Professor J-Y Reginster said: "Protelos is the first and only anti-osteoporotic treatment to show five-year, evidence-based efficacy against both vertebral and non-vertebral fractures and should be considered for sustained first-line therapy in women with postmenopausal osteoporosis."
The investigators observed that current adherence rates of women taking osteoporosis drugs (mainly bisphosphonates) are less than 25% – suggesting that compliance will have to improve if patients are to fully benefit from Protelos.
Unlike other treatments, Protelos has a unique dual effect on bones by increasing the creation of new bone while also decreasing the gradual loss of bone mass called resorption.
Protelos received EU approval in September 2004 to reduce the risk of vertebral and hip fractures in patients with postmenopausal osteoporosis.






